CU20170176A7 - Composición farmacéutica que comprende péptido tipo apl - Google Patents

Composición farmacéutica que comprende péptido tipo apl

Info

Publication number
CU20170176A7
CU20170176A7 CU2017000176A CU20170176A CU20170176A7 CU 20170176 A7 CU20170176 A7 CU 20170176A7 CU 2017000176 A CU2017000176 A CU 2017000176A CU 20170176 A CU20170176 A CU 20170176A CU 20170176 A7 CU20170176 A7 CU 20170176A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
type peptide
apl type
seq
inflammatory diseases
Prior art date
Application number
CU2017000176A
Other languages
English (en)
Other versions
CU24508B1 (es
Inventor
Pérez Vladimir Armando Besada
Horta María Del Carmen Domínguez
López Luis Javier González
Abad Cruz Matilde López
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma filed Critical Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma
Priority to CU2017000176A priority Critical patent/CU24508B1/es
Priority to EP18845399.7A priority patent/EP3733196B1/en
Priority to BR112020013033-8A priority patent/BR112020013033A2/pt
Priority to JP2020536159A priority patent/JP7209000B2/ja
Priority to KR1020207021876A priority patent/KR20200105869A/ko
Priority to ARP180103792A priority patent/AR114389A1/es
Priority to CA3086280A priority patent/CA3086280A1/en
Priority to ES18845399T priority patent/ES2960415T3/es
Priority to US16/958,586 priority patent/US20200353040A1/en
Priority to PCT/CU2018/050007 priority patent/WO2019129315A1/es
Priority to CN201880090158.9A priority patent/CN111741763A/zh
Priority to RU2020124953A priority patent/RU2778402C2/ru
Priority to MX2020006840A priority patent/MX2020006840A/es
Publication of CU20170176A7 publication Critical patent/CU20170176A7/es
Priority to ZA2020/04658A priority patent/ZA202004658B/en
Publication of CU24508B1 publication Critical patent/CU24508B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La invención provee una composición farmacéutica que comprende el péptido tipo APL identificado como SEQ ID No. 1, el tampón acetato de sodio a pH 3,9- 4,7; y al menos un azúcar estabilizante seleccionado entre Ia sacarosa y Ia trehalosa. Dicha composición farmacéutica es útil para Ia fabricación de un medicamento para tratar las enfermedades inflamatorias relacionadas con un aumento de los neutrófilos o de Ia citrulinación de proteínas. Entre estas enfermedades inflamatorias se encuentran Ia artritis reumatoide (AR), Ia artritis idiopática juvenil (AIJ), Ia espondilitis anquilosante (EA), Ia enfermedad de Alzheimer, y Ia fibrosis hepática o pulmonar. La invención tambien revela un método para el tratamiento de dichas enfermedades, mediante Ia administración de una cantidad terapéuticamente efectiva de Ia<br /> composición farmacéutica del péptido tipo APL identificado como SEQ ID No. 1.<br /> </p>
CU2017000176A 2017-12-29 2017-12-29 Composición farmacéutica que comprende péptido tipo apl CU24508B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU2017000176A CU24508B1 (es) 2017-12-29 2017-12-29 Composición farmacéutica que comprende péptido tipo apl
ES18845399T ES2960415T3 (es) 2017-12-29 2018-12-21 Composición farmacéutica que comprende un péptido de tipo ligando peptídico alterado (LPA)
US16/958,586 US20200353040A1 (en) 2017-12-29 2018-12-21 Pharmaceutical Composition Comprising an APL Type Peptide
JP2020536159A JP7209000B2 (ja) 2017-12-29 2018-12-21 Ａｐｌ型ペプチドを含む医薬組成物
KR1020207021876A KR20200105869A (ko) 2017-12-29 2018-12-21 Apl 형 펩타이드를 포함하는 약제학적 조성물
ARP180103792A AR114389A1 (es) 2017-12-29 2018-12-21 Composición farmacéutica que comprende péptido tipo apl
CA3086280A CA3086280A1 (en) 2017-12-29 2018-12-21 Pharmaceutical composition comprising an apl peptide
EP18845399.7A EP3733196B1 (en) 2017-12-29 2018-12-21 Pharmaceutical composition comprising an altered peptide ligand (apl) type peptide
BR112020013033-8A BR112020013033A2 (pt) 2017-12-29 2018-12-21 composição farmacêutica, uso da composição farmacêutica, e, método para tratamento de uma doença inflamatória.
PCT/CU2018/050007 WO2019129315A1 (es) 2017-12-29 2018-12-21 Composición farmaceutica que comprende un peptido tipo apl
CN201880090158.9A CN111741763A (zh) 2017-12-29 2018-12-21 包含apl型肽的药用组合物
RU2020124953A RU2778402C2 (ru) 2017-12-29 2018-12-21 Фармацевтическая композиция, содержащая пептид apl-типа
MX2020006840A MX2020006840A (es) 2017-12-29 2018-12-21 Composicion farmaceutica que comprende un peptido tipo apl.
ZA2020/04658A ZA202004658B (en) 2017-12-29 2020-07-28 Pharmaceutical composition comprising an apl type peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2017000176A CU24508B1 (es) 2017-12-29 2017-12-29 Composición farmacéutica que comprende péptido tipo apl

Publications (2)

Publication Number Publication Date
CU20170176A7 true CU20170176A7 (es) 2019-08-06
CU24508B1 CU24508B1 (es) 2021-04-07

Family

ID=65351834

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000176A CU24508B1 (es) 2017-12-29 2017-12-29 Composición farmacéutica que comprende péptido tipo apl

Country Status (13)

Country Link
US (1) US20200353040A1 (es)
EP (1) EP3733196B1 (es)
JP (1) JP7209000B2 (es)
KR (1) KR20200105869A (es)
CN (1) CN111741763A (es)
AR (1) AR114389A1 (es)
BR (1) BR112020013033A2 (es)
CA (1) CA3086280A1 (es)
CU (1) CU24508B1 (es)
ES (1) ES2960415T3 (es)
MX (1) MX2020006840A (es)
WO (1) WO2019129315A1 (es)
ZA (1) ZA202004658B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3151107A1 (en) * 2019-08-14 2021-02-18 The Regents Of The University Of California Car-t cells specific for modified proteins in extracellular spaces
CU24626B1 (es) 2019-12-26 2022-11-07 Centro Nac De Biopreparados Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
WO2024017423A1 (es) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Péptido para el tratamiento de enfermedades relacionadas con afectaciones en la apolipoproteina ai o la transtirretina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23504A1 (es) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
EP2231180B1 (en) 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
DK2294086T3 (en) * 2008-06-04 2018-01-02 Modiquest B V ANTI-INFLAMMATORY AGENTS
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Also Published As

Publication number Publication date
EP3733196B1 (en) 2023-08-30
JP2021508711A (ja) 2021-03-11
RU2020124953A3 (es) 2022-01-31
AR114389A1 (es) 2020-09-02
BR112020013033A2 (pt) 2020-12-01
JP7209000B2 (ja) 2023-01-19
WO2019129315A1 (es) 2019-07-04
ES2960415T3 (es) 2024-03-04
ZA202004658B (en) 2022-01-26
MX2020006840A (es) 2020-09-03
CN111741763A (zh) 2020-10-02
CA3086280A1 (en) 2019-07-04
EP3733196A1 (en) 2020-11-04
RU2020124953A (ru) 2022-01-31
CU24508B1 (es) 2021-04-07
KR20200105869A (ko) 2020-09-09
US20200353040A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CU20170176A7 (es) Composición farmacéutica que comprende péptido tipo apl
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
PE20231949A1 (es) VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
MX2019005088A (es) Formulaciones de virus adeno-asociados.
RU2017101667A (ru) Фармацевтические композиции
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
AR108631A1 (es) Formulación de neurotoxinas
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
JP2017516848A5 (es)
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
PE20210918A1 (es) Composiciones y metodos para el tratamiento de la distrofia macular
AR120171A1 (es) Composición farmacéutica de vector de virus adenoasociado y métodos
BR112017002741A2 (pt) peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
JP2017503505A5 (es)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
AR086672A1 (es) Formulaciones de furina recombinante
JP2015525237A5 (es)
PE20190347A1 (es) Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant
MX2022004799A (es) Composiciones y metodos para el tratamiento de los trastornos de almacenamiento de glucogeno.